Journal article
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial
JP Neoptolemos, MJ Moore, TF Cox, JW Valle, DH Palmer, AC McDonald, R Carter, NC Tebbutt, C Dervenis, D Smith, B Glimelius, RM Charnley, F Lacaine, AG Scarfe, MR Middleton, A Anthoney, P Ghaneh, CM Halloran, MM Lerch, A Oláh Show all
JAMA | Published : 2012
Abstract
Context: Patients with periampullary adenocarcinomas undergo the same resectional surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant chemotherapy has been shown to have a survival benefit for pancreatic cancer, there have been no randomized trials for periampullary adenocarcinomas. Objective: To determine whether adjuvant chemotherapy (fluorouracil or gemcitabine) provides improved overall survival following resection. Design, Setting, and Patients: The European Study Group for Pancreatic Cancer (ESPAC)-3 periampullary trial, an open-label, phase 3, randomized controlled trial ( July 2000-May 2008) in 100 centers in Europe, Australia, Japan, and Canada. Of t..
View full abstractGrants
Funding Acknowledgements
The study was supported by Cancer Research United Kingdom; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia, Cancer Councils of New South Wales, Queensland, Victoria and South Australia and The Australasian Gastro-Intestinal Trials Group. JPN is part funded Liverpool NIHR Pancreas Biomedical Research Unit. MM is part funded Oxford NIHR Biomedical Research Centre.